C9orf72
白质
磁共振弥散成像
神经突
灰质
萎缩
肌萎缩侧索硬化
病理
生物标志物
磁共振成像
核医学
医学
放射科
生物
失智症
疾病
遗传学
痴呆
体外
作者
Junhao Wen,Hui Zhang,Daniel C. Alexander,Stanley Durrleman,Alexandre Routier,Daisy Rinaldi,Marion Houot,Philippe Couratier,Didier Hannequin,Florence Pasquier,Jiaying Zhang,Olivier Colliot,Isabelle Le Ber,Anne Bertrand
标识
DOI:10.1136/jnnp-2018-318994
摘要
Objective To assess the added value of neurite orientation dispersion and density imaging (NODDI) compared with conventional diffusion tensor imaging (DTI) and anatomical MRI to detect changes in presymptomatic carriers of chromosome 9 open reading frame 72 ( C9orf72 ) mutation. Methods The PREV-DEMALS (Predict to Prevent Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis) study is a prospective, multicentre, observational study of first-degree relatives of individuals carrying the C9orf72 mutation. Sixty-seven participants (38 presymptomatic C9orf72 mutation carriers (C9+) and 29 non-carriers (C9−)) were included in the present cross-sectional study. Each participant underwent one single-shell, multishell diffusion MRI and three-dimensional T1-weighted MRI. Volumetric measures, DTI and NODDI metrics were calculated within regions of interest. Differences in white matter integrity, grey matter volume and free water fraction between C9+ and C9− individuals were assessed using linear mixed-effects models. Results Compared with C9− , C9+ demonstrated white matter abnormalities in 10 tracts with neurite density index and only 5 tracts with DTI metrics. Effect size was significantly higher for the neurite density index than for DTI metrics in two tracts. No tract had a significantly higher effect size for DTI than for NODDI. For grey matter cortical analysis, free water fraction was increased in 13 regions in C9+ , whereas 11 regions displayed volumetric atrophy. Conclusions NODDI provides higher sensitivity and greater tissue specificity compared with conventional DTI for identifying white matter abnormalities in the presymptomatic C9orf72 carriers. Our results encourage the use of neurite density as a biomarker of the preclinical phase. Trial registration number NCT02590276 .
科研通智能强力驱动
Strongly Powered by AbleSci AI